Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoshi Yoshihara

Showing results (141-150 of 145) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 145 results.
Nature Cancer|March 25, 2025
CAR T or NK cells targeting mismatched HLA-DR molecules in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantShunya Ikeda, Kana Hasegawa, Yosuke Kogue, et al.
Science Translational Medicine|February 16, 2022
Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chainKana Hasegawa, Shunya Ikeda, Moto Yaga, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 4, 2018
Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line TreatmentMasaya Okada, Jun Imagawa, Hideo Tanaka, et al.
The New England Journal of Medicine|December 9, 2025
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple MyelomaLuciano J Costa, Nizar J Bahlis, Aurore Perrot, et al.
Nature|July 8, 2026
Chromatin landscape and epigenetic heterogeneity of acute myeloid leukaemiaYotaro Ochi, Markus Liew-Littorin, Yasuhito Nannya, et al.
Pageof 15

Showing results (141-150 of 145) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 145 results.
Nature Cancer|March 25, 2025
CAR T or NK cells targeting mismatched HLA-DR molecules in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantShunya Ikeda, Kana Hasegawa, Yosuke Kogue, et al.
Science Translational Medicine|February 16, 2022
Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chainKana Hasegawa, Shunya Ikeda, Moto Yaga, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 4, 2018
Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line TreatmentMasaya Okada, Jun Imagawa, Hideo Tanaka, et al.
The New England Journal of Medicine|December 9, 2025
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple MyelomaLuciano J Costa, Nizar J Bahlis, Aurore Perrot, et al.
Nature|July 8, 2026
Chromatin landscape and epigenetic heterogeneity of acute myeloid leukaemiaYotaro Ochi, Markus Liew-Littorin, Yasuhito Nannya, et al.
Pageof 15